{"id":47470,"date":"2022-08-19T12:01:43","date_gmt":"2022-08-19T10:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-monkeypox-therapeutics-market-analysis-research-report-2022-researchandmarkets-com\/"},"modified":"2022-08-19T12:01:43","modified_gmt":"2022-08-19T10:01:43","slug":"global-monkeypox-therapeutics-market-analysis-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-monkeypox-therapeutics-market-analysis-research-report-2022-researchandmarkets-com\/","title":{"rendered":"Global Monkeypox Therapeutics Market Analysis\/Research Report 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Monkeypox Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Treatment), By End User, By Region”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nGlobal Monkeypox therapeutics market is projected to register growth at a significant CAGR during the forecast period, 2023-2027\n<\/p>\n

\nThe market growth can be attributed to the sudden outburst of the viral infection among the population across Europe and United States. In the year 2003, Monkeypox caused a commotion because it spread quickly, and the number of affected patients exceeded 40 in a matter of weeks.\n<\/p>\n

\nAlthough the disease spread was relatively well-controlled, the recent outbreak of infection and rapidly increasing cases pose a threat for another possible pandemic. Hence, the demand for effective treatment, vaccination, and other rare disease therapeutics are expected to support the growth of the global Monkeypox therapeutics market over the next five years.\n<\/p>\n

\nThere is currently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and an increase in demand for pain and itch relief due to boils and rashes are positively influencing the growth of the global Monkeypox therapeutics market.\n<\/p>\n

\nMonkeypox is a viral infection that spreads like a highly communicable disease through mere touch and use of infected patient’s material. The virus is related to smallpox, and the vaccination and drugs used to control smallpox are also somewhat effective against Monkeypox diseases.\n<\/p>\n

\nAlthough no specific vaccine or treatment drug has yet been commercialised, research is still ongoing. Patients with compromised immunity, those suffering from chronic disease, certain skin conditions such as eczema, those recovering from a recent pandemic, and those suffering from other anti-viral infections are all at high risk of contracting the Monkeypox.\n<\/p>\n

\nGrowing demand for timely vaccines and potential disease treatments may support the growth of the global Monkeypox therapeutics market in the next five years. Governments are actively investing in the research and development of effective vaccines and drugs to control disease spread and treat affected patients. In addition, the government is taking steps to promote drug development using genetic engineering tools in order to provide vaccination in the event that the virus evolves and affects a larger portion of the population.\n<\/p>\n

\nGenomic sequencing for the virus would elucidate the specific infection-causing sequences, which could aid in the early diagnosis of the viral infection and the development of effective vaccines for the population at risk of infection in the coming years. Furthermore, rising healthcare expenditures by the population is fuelling growing investments for the development to new vaccines, which is likely to aid the global Monkeypox therapeutics market in the next five years.\n<\/p>\n

\nThe global Monkeypox therapeutics market segmentation is based on treatment, end user, regional distribution, and competitive landscape. Based on treatment, the market is divided into smallpox vaccine, antivirals, and vaccinia immune globulin (VIG). The smallpox vaccine segment is anticipated to hold the largest share in the global Monkeypox therapeutics market due to the rising number of cases of Monkeypox.\n<\/p>\n

\nObjective of the Study:<\/strong>\n<\/p>\n